

Insulin Resistance and Alzheimer's Disease: A Novel Therapeutic Target

Suzanne Craft

Geriatric Research, Education, and Clinical Center
VA Puget Sound

Professor of Psychiatry and Behavioral Sciences
University of Washington School of Medicine



Overview

- Insulin plays a role in cognition and normal brain function
- Dysregulation of insulin increases risk for AD and other neurodegenerative diseases
- Potential mechanisms of increased risk: Effects on inflammation and β -amyloid
- Therapeutic applications: Effects of treating insulin resistance and normalizing CNS insulin

Insulin and the Brain

- Insulin crosses BBB via saturable receptor-mediated transcytosis (Banks et al, 97)
- Insulin receptors have synaptic localization in hippocampus and throughout cortex (Apelt et al, 2001)
- Increases glucose utilization in specific brain regions (Bingham et al, 2002)
- Increases levels of dopamine, acetylcholine, norepinephrine (Figlewicz et al, 1993)
- Modulates membrane potentials, membrane expression of NMDA receptors, and neuronal firing/LTP in hippocampus and EC (Skeberdis et al, 2001)
- Enhances memory at **optimal** dose

Chronic Effects of Insulin: Too Much of a Good Thing

- Insulin typically secreted and cleared quickly
- High, chronic elevations problematic
 - Reduced brain insulin uptake
(Schwartz et al, 1990; Stein et al, 1987)
 - Reduced neurotransmitter levels
 - Reduced glucose utilization (periphery and CNS?)
 - Memory impairment

Insulin Resistance and Alzheimer's Disease

- Insulin resistance/hyperinsulinemia increase risk of AD and memory impairment (Ott et al, 1999; Peila et al, 2002; Luchsinger et al, 2004)
- Risk increases with age (Ryan et al, 2001)
- Insulin resistance a particular risk factor for AD patients without the APOE-e4 allele (Kuusisto et al, 97; Liotsa et al, 02; Craft et al, 03)
- Insulin may modulate risk in part through effects on A β 42
 - ➔ Modulates A β 42 levels in vitro
 - ➔ Enhances release, regulates degradation by IDE (Gasparini et al, 2001; Qiu et al, 2001; Zhao et al, 2004)

Does Insulin Affect CNS Levels of A β ?

- Will insulin administration raise A β 42 levels in CSF, consistent with *in vitro* effects of insulin on A β release & degradation?
- Will effects differ according to age?
- Will results be related to changes in biomarkers associated with inflammation?

Methods

Fasted Subjects (n=16, mean age = 68.7)


Separate days, counterbalanced order

Saline

Insulin (85 μ U/ml)


Dextrose (95 mg/dl)

Insulin/dextrose or saline infusion







Effects of Insulin on CSF A β 42 Levels in Normal Older Adults: Results

Insulin-induced change in A β 42
is correlated with age



Results

Cytokines




*p-values < .0001-.002 Fishel et al. *Neurology*, 2005

Results

CSF F2-IsoP


CSF F2-Isoprostane levels increase
in response to insulin



* $p < .01$

Results


Insulin-induced change in CSF A β 42 is correlated with F2-Isoprostane levels for the **OLDER** normal adults




Does insulin have similar role in A β regulation in periphery?

- A β cleared in liver and other peripheral sites
(Ghiso et al 04)
- Plasma A β elevated for some AD patients, declines with progression (Mayeux et al. 03; Ertekin-Taner et al. 04)
- A β transported between periphery and brain
(Mackic et al. 02; DeMattos et al. 02)
- IGF-1 and insulin increase levels of carrier proteins that bind A β and regulate its transport (Carro et al. 02)
- High plasma A β may obstruct clearance from or increase transport into brain

Dose-response effects of intravenous insulin on plasma A β 42



Model of Peripheral Insulin Resistance & Hyperinsulinemia Effects on A β Regulation




Therapeutic Implications

- Raising plasma insulin invoked age-related increases in CSF A β 42 & inflammatory markers for normal adults, raised plasma A β for AD patients
- Mechanisms through which insulin resistance increases risk of AD with age?
- Treatment of insulin resistance that lowers insulin and improves its effectiveness may be of therapeutic benefit
- PPAR γ agonists (TZDs) promising because they increase peripheral insulin sensitivity, reduce peripheral insulin and inflammation



Rosiglitazone Treatment Affects Brain A β 42, IDE Levels & Memory in AD Mouse Model

9 month old male TG2576 mice treated for 4 mos with 4mg / kg rosiglitazone or placebo




Rosiglitazone Treatment Affects Brain A β 42, IDE Levels & Memory in AD Mouse Model

9 month old male TG2576 mice treated for 4 mos with 4mg / kg rosiglitazone or placebo





Hippocampal IDE mRNA




Hippocampal IDE mRNA

Rosiglitazone Treatment Affects Brain A β 42, IDE Levels & Memory in AD Mouse Model

9 month old male TG2576 mice treated for 4 mos with 4mg / kg rosiglitazone or placebo



Hippocampal IDE mRNA



Working Memory Errors

Effects of Rosiglitazone on Cognition in Patients with Early AD or Amnestic MCI


Subjects

- Amnestic MCI or early AD (Petersen et al. 2003 or NINCDS/ADRDA criteria), CDR = 0.5 or 1.0, MMSE > 15
- No diabetes or other relevant medical conditions
- No meds with known CNS effects other than ChEI

Double-blind
Randomized (2:1)

Placebo (n=10)

Rosiglitazone (n=20)



Sample Demographics


	Rosi (n = 20)	Placebo (n = 10)
Age years	72.8 (6.6)	73.3 (6.0)
AD/MCI	14/6	7/3
Sex (F/M)	6/14	3/7
MMSE	22.7 (4.5)	23.3 (5.4)
BMI	24.2 (2.7)	24.4 (4.2)
ChEI +	25%	20%

Cognitive Battery

- **General Cognition**
Mini Mental State Exam
- **Memory**
Buschke Reminding Test
Story Recall
- **Attention**
Stroop Interference Test
Trail-Making Test
- **Language**
Semantic Fluency
Picture Naming
Narrative Writing

Results

Delayed Verbal Memory



Results

- Plasma insulin levels lower after 6 months for rosi-treated group ($p=.0026$)
- Improvement in memory, selective attention, and verbal fluency related to metabolic treatment response – *indexed by reduced insulin levels*
- No relationship between treatment response and stage of disease


Rosiglitazone XR Study AVA100193

Risner et al., *Pharmacogenomics J*, 2006

- Population:
 - Mild to moderate Alzheimer's Disease (MMSE 16 – 26)
 - Treatment naïve, receiving no AD pharmacotherapies
- Primary Objectives:
 - Cognitive function: *ADAS-cog*
 - Clinical response: *CIBIC+*
- Secondary Objectives:
 - Other Cognitive/Functional assessments: *NPI, MMSE*
 - Safety, tolerability: *AEs, hematology, etc*
 - Insulin sensitivity, glycemic control: *insulin, glucose, etc*
 - Pharmacogenetics: *interaction by APOE genotype*

GlaxoSmithKline AVA100193

24-week, DB, PBO-controlled, dose-ranging study to investigate rosiglitazone in AD



GSK Rosiglitazone Trial : AVA100193

Demographics

	Placebo (N=122)	RSG 2mg (N=127)	RSG 4mg (N=130)	RSG 8mg (N=132)
Gender:				
Female	77 (63%)	71 (56%)	73 (56%)	87 (66%)
Male	45 (37%)	56 (44%)	57 (44%)	45 (34%)
Age:				
Mean (SD)	71.8 (8.2)	70.9 (8.5)	69.7 (9.0)	70.5 (8.5)
Min-Max	50 - 85	50 - 85	50 - 85	51 - 85
BMI:				
Mean (SD)	25.67 (3.8)	25.51 (4.0)	25.88 (3.4)	25.82 (3.9)
MMSE :				
Mean	20.8 (3.44)	21.3 (3.07)	21.6 (2.87)	21.4 (3.20)

Analysis Summary :

Change from Baseline in ADAS-Cog at Week 24 (LOCF)

Treatment	N	Least Squares Mean (SE)	Treatment Comparison (RSG vs. Placebo)	
			Difference	p-value
Placebo	122	-0.4 (0.55)		
RSG 2 mg	126	-0.2 (0.54)	0.25	0.74
4 mg	129	-0.9 (0.54)	-0.46	0.52
8 mg	131	-0.7 (0.53)	-0.27	0.71


ADAS-cog assesses various cognitive abilities such as memory, orientation in time and place, etc. Scores range from 0 to 70; higher scores indicate greater dysfunction while negative change indicates improvement

Analysis Summary :

Change from Baseline in ADAS-Cog at Week 24 by Treatment & APOE4 Carriage

APOE4 Carriage	Treatment (n)	LS Mean (SE)	<i>p</i> -values for Trt Difference*	<i>p</i> -value for Interaction
No	Placebo (n =43)	1.10 (0.96)	0.048 0.067 0.024	0.014
	RSG 2 mg (n=49)	-1.35 (0.90)		
	4 mg (n=45)	-1.21 (0.90)		
	8 mg (n=42)	-1.84 (0.95)		
Yes	Placebo (n=35)	-1.10 (1.04)	0.012 0.29 0.29	
	RSG 2 mg (n=36)	2.46 (1.03)		
	4 mg (n=34)	0.39 (1.05)		
	8 mg (n=36)	0.39 (1.03)		


Mean Change from Baseline in ADAS-Cog for APOE4- Subjects Only




Intranasal Insulin & the CNS

Intranasal insulin administration:

- Increases CSF insulin and improves memory within 30-min in young, healthy adults without changing plasma glucose or insulin (Born et al. 02; Benedict et al. 04)
- Insulin-like peptide signal measurable in rat hippocampus, amygdala, frontal cortex 30 min after intranasal administration (Thorne et al. 04)
- Can intranasal insulin administration “normalize” reduced CNS insulin that characterizes some patients with AD, and thereby improve memory?



Intranasal Pathways to the Brain in Humans




- Bulk flow along rostral (olfactory) or caudal (trigeminal) perivascular channels; agents reach brain in minutes
(Thorne et al. 01)
- Axonal transport through olfactory neurons, which require hours to reach brain

Study 1

Methods

Procedure



Study 1

Methods


Subjects

Mean (sd)	Normal	AD	
	Controls	$\epsilon 4-$	$\epsilon 4+$
N	35	14	12
Age (yrs)	75 (6)	77 (6)	77 (5)
Education	15 (2)	14 (2)	15 (2)
BMI (kg/m²)	26 (3)	25 (3)	25 (3)
DRS (max=144)	140 (4)	127 (10)	125 (11)

Study 1

Results

Total Story Recall



Study 2

Methods


Subjects

Mean (sd)	AD	
	$\epsilon 4-$	$\epsilon 4+$
N	11	23
Age (yrs)	76 (4)	77 (8)
Education	14 (3)	15 (3)
BMI (kg/m²)	26 (3)	26 (5)
DRS (max=144)	131 (9)	130 (13)

Study 2

Results

Total Story Recall



* $p < 0.05$

Summary

- Insulin has numerous actions in CNS that affect cognition
- Hyperinsulinemia / insulin resistance increases inflammation and CSF A β 42
- These conditions may be potent AD risk factors, particularly for patients *without* APOE ϵ 4-
- Treatment with PPAR γ agonist rosiglitazone & intranasal insulin enhance cognition in AD / amnestic MCI – may represent novel therapeutic strategies for this subgroup of patients

Collaborators

Sanjay Asthana, MD

John Breitner, MD, MPH

David Cook, PhD

Mark Fishel, MD

Pattie Green, PhD

William Frey, II, PhD

Steven Kahn, MB, ChB

James Leverenz, MD

Thomas Montine, MD, PhD

Ward Pedersen, PhD

Elaine Peskind, MD

Stephen Plymate, MD

Murray Raskind, MD

This work was funded by the Department of Veterans Affairs,
NIA R01 AG10880, ISOA, and GlaxoSmithKline.

Insulin and Neurodegenerative Disease Research Team

Pamela Asberry, RN

Laura Baker, PhD

Meabh Carter

Darla Chapman, RN

Brenna Cholerton, PhD

Tracia Clark

Donna Davis, RN

Karen Enstrom, RN

Mark Fishel, MD

Laura Fisher

Laura Frank, PhD

Maggie Gillet

Karen Hyde, RN

Jamie Iliff

Jake Kulstad

Marcos Marques, MD

Pamela McMillan, PhD

Amy Morgan

Mark Reger, PhD



Stennis Watson, PhD

Magdalena Wojtowicz

Exclusionary Criteria

- Significant neurological disease other than AD
- Use of antidepressants, antipsychotics, anticonvulsants, anticoagulants, anxiolytics or sedatives
- Major psychiatric disorders
- Severe head trauma with LOC >30 min or with permanent sequelae
- Uncontrolled chronic pain
- Radiation treatment (current or recent)
- CVA
- CHF
- COPD
- Vision loss
- Diabetes (diagnosed)
- Alcohol and drug abuse/dependence
- Liver disease
- Severe medical illness (e.g., uncontrolled HTN, cancer not in remission > 1 year, thyroid disease, cardiac arrhythmia, renal and hepatic disease)

Model-adjusted Mean Change from Baseline in ADAS-cog by APOE4 status



Safety Data

- Safety monitoring (labs, physical exam) at weeks 2 and 4, then monthly
- No changes in fasting glucose, lipids, LFTs, renal indices
- Two SAEs: Myocardial infarction (1 placebo) and lacunar infarction (1 rosi)
- Other AEs: mild anemia (1 placebo, 3 rosi), mild edema (1 rosi)

AVA100193: Key Safety Results, ITT Population

Summary of AEs/SAEs	Placebo (N = 124)	RSG 2mg (N = 128)	RSG 4mg (N = 131)	RSG 8mg (N = 135)
Any Tx emergent AE	44 (35%)	36 (28%)	41 (31%)	46 (34%)
Any SAE	7 (6%)	6 (5%)	3 (2%)	9 (7%)

AEs of Special Interest

	Placebo (N = 124)	RSG 2mg (N = 128)	RSG 4mg (N = 131)	RSG 8mg (N = 135)
Oedema	0	3 (2%)	1 (<1%)	3 (2%)
Oedema peripheral	0	0	4 (3%)	3 (2%)
Eyelid oedema	0	1 (<1%)	0	1 (<1%)
Periorbital oedema	1 (<1%)	0	0	0
Anaemia	0	1 (<1%)	0	2 (1%)
Cardiac failure	1 (<1%)	0	0	1 (<1%)
Cardiac failure (acute)	0	0	1 (<1%)	0
Alanine aminotransferase ↑	0	0	0	1 (<1%)
Aspartate aminotransferase ↑	0	0	0	1 (<1%)

No new safety concerns identified in AVA100193 compared with the well established safety profile of rosiglitazone